KalVista Pharmaceuticals is a biopharmaceutical company discovering, developing and commercializing oral protease inhibitor drugs based on deep expertise in the kallikrein-kinin system.
Our commitment to rigorous science is driven by our determination to better address treatment needs for patients, beginning with our first investigational product for hereditary angioedema (HAE), a rare genetic disease with unpredictable attacks of tissue swelling that can be life threatening.